Cerebrolysin vs CJC-1295 (without DAC / Mod GRF 1-29)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

CerebrolysinCJC-1295 (without DAC / Mod GRF 1-29)
CategoryPeptidesPeptides
Standard DoseResearch indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization.Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
TimingMorning administration preferred for cognitive effects. IV infusion over 15-20 minutes.Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.
Cycle Duration10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance.12-24 week cycles with 4-8 week breaks.
Evidence Levelmoderate_humanmoderate_human
A

Cerebrolysin

Peptides

Mechanism

Cerebrolysin is a porcine brain-derived peptide preparation containing a standardized mixture of low-molecular-weight neuropeptides (<10 kDa) and free amino acids obtained through enzymatic proteolysis. It exerts multimodal neurotrophic effects by simultaneously upregulating VEGF, BDNF, IGF-1, and NGF while downregulating TNF-alpha. Cerebrolysin increases furin protease concentration, which promotes pro-NGF to mature NGF conversion. It activates TrkB receptor signaling (BDNF/TrkB/CREB pathway), inhibits neuronal apoptosis, reduces microglial activation, and promotes neurogenesis.

Standard Dosing

Research indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization.

Timing

Morning administration preferred for cognitive effects. IV infusion over 15-20 minutes.

Cycle Duration

10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance.

Side Effects

  • Injection site reactions
  • Dizziness
  • Headache
  • Agitation
  • Fever (rare)
  • Hypersensitivity reactions

Contraindications

  • Epilepsy/seizure disorders
  • Severe renal impairment
  • Pregnancy and breastfeeding
  • Allergy to porcine products

Best Stacking Partners

P21SemaxSelank

Mechanism

Mod GRF 1-29 (Modified Growth Hormone Releasing Factor, amino acids 1-29) is a truncated and modified GHRH analog that binds to GHRH receptors on anterior pituitary somatotrophs, activating cAMP via Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways. Without the DAC moiety, it has a short half-life of approximately 30 minutes, producing acute GH pulses that more closely mimic natural pulsatile GH secretion. It also stimulates pituitary gene transcription of GH mRNA, preserving endogenous pituitary reserve.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.

Cycle Duration

12-24 week cycles with 4-8 week breaks.

Side Effects

  • Flushing post-injection
  • Head rush
  • Hunger increase
  • Water retention (mild)
  • Tingling in extremities

Contraindications

  • Active cancer
  • Diabetic retinopathy
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6Hexarelin

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →